Hesham Abboud, MD
Neurology · Cleveland, OHNPI 1720318355
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $264,011 of the $362,590 with a category attached, or 72.8%. 27 manufacturers reported payments, led by Biogen at 31.1% of the total. Reporting peaked in 2019 at $86,771 and has fallen 51.6% since, to $41,998 in 2025. Among neurology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 423 payments — averaging $857.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$113K
- Genentech USA, Inc.$80K
- Amgen$66K
- AstraZeneca$33K
- E.r. Squibb & Sons, L.L.C.$18K
- Genentech, Inc.$16K
- plus $37K from 21 others
Across 105 payments — averaging $7017.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$401K
- Genentech, Inc.$146K
- Bristol Myers Squibb$77K
- Roche Products Limited$51K
- Sanofi$36K
- F. Hoffmann-la Roche AG$18K
- plus $9K from 1 others
What the payments were for
- Consulting fees$66,80718%
- Speaking & faculty fees$264,01173%
- Travel & lodging$20,4626%
- Food & beverage$11,1263%
- Education$1840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 79 | $112,632 |
| Genentech USA, Inc. | 91 | $79,832 |
| Amgen(2 entities) | 84 | $65,583 |
| AstraZeneca | 42 | $33,142 |
| E.r. Squibb & Sons, L.L.C. | 9 | $18,055 |
| Genentech, Inc. | 10 | $15,915 |
| Bristol Myers Squibb | 22 | $12,598 |
| TG Therapeutics, Inc. | 10 | $6,779 |
| F. Hoffmann-la Roche AG | 10 | $6,330 |
| Sanofi | 3 | $4,311 |
| Axonics, Inc. | 1 | $2,739 |
| Roche Products Limited | 4 | $1,589 |
| Cycle Pharmaceuticals Inc | 1 | $1,300 |
| Abbott | 3 | $750 |
| Novartis | 25 | $427 |
| AbbVie | 7 | $196 |
| Lilly USA, LLC | 6 | $121 |
| Portola Pharmaceuticals, LLC | 4 | $57 |
| Johnson & Johnson | 3 | $48 |
| UCB, Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| EMD Serono, Inc. | 1 | $17 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCREVUS$69,010
- UPLIZNA$57,813
- Vumerity$41,973
- TYSABRI$38,634
- TECFIDERA$28,835
- Enspryng$15,303
- SOLIRIS$12,694
- ZEPOSIA$11,522
- BRIUMVI$6,666
- Non-Covered Product$4,792
- DISEASE STATE$4,311
- AVONEX$3,013
- PLEGRIDY$3,013
- Axonics$2,739
- Nityr$1,300
- Infinity DBS Pulse Generators$729
- Ocrevus Zunovo$126
How this compares
$362,590 in reported general payments places this provider in the 95th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EnspryngSatralizumab-Mwge | 24 | $516,794 |
| Kesimpta PenOfatumumab | 41 | $390,053 |
| ZeposiaOzanimod Hydrochloride | 18 | $210,389 |
| Dalfampridine ErDalfampridine | 17 | $2,987 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 118 | $2,918 |
| Mycophenolate Mofetil | 18 | $2,428 |
| Baclofen | 60 | $1,829 |
| Dantrolene Sodium | 12 | $890 |
| Gabapentin | 37 | $779 |
| Primidone | 25 | $411 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 14 | $352 |
| Tizanidine Hcl | 32 | $206 |
| Topiramate | 11 | $199 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 13 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Enspryng | $79,832 | $516,79424 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $18,055 | $210,38918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 702 neurology providers in Ohio.
Other neurology in Cleveland
- Imad NajmCleveland$373K
- Robert BermelCleveland$302K
- Eric BaronCleveland$297K
- Robert FoxCleveland$296K
- Aarushi SunejaCleveland$269K
- Mary WillisCleveland$254K
- Benjamin WalterCleveland$210K
- Aasef ShaikhCleveland$186K
- Maryann MaysCleveland$173K
- Mary RenselCleveland$154K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.